31/19. Fluorodopa F 18- (Oct 2019)- Adiagnostic agent for use in positron emission tomography to help patients with Parkinsonian Syndrome
Drug Name:
31/19. Fluorodopa F 18- (Oct 2019)- Adiagnostic agent for use in positron emission tomography to help patients with Parkinsonian Syndrome
List Of Brands:
Indication Type Description:
Indication:
BRIEF SUMMARY
FLUORADOPA-(Oct 2019)
Indn- Adiagmostic agent for use in positron emission tomography (PET) to help diagnose patients with suspected Parkinsonian Syndrome
Comp-
ADR-
CI-
Pat Inform-
==================================================================
U.S. FDA APPROVED DRUGS DURING 2019
Sr.No- 31.
Name of the Drug- Fluorodopa
Active Ingredient - Fluorodopa F 18
Pharmacological Classification-
Adiagmostic agent for use in positron emission tomography (PET) to help diagnose patients with suspected Parkinsonian Syndrome
-
Date of Approval- October 2019
Adiagmostic agent for use in positron emission tomography (PET) to help diagnose patients with suspected Parkinsonian Syndrome
